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IMPORTANCE Breast milk substitutes (BMS) are important nutritional products evaluated in
clinical trials. Concerns have been raised about the risk of bias in BMS trials, the reliability of
claims that arise from such trials, and the potential for BMS trials to undermine breastfeeding
in trial participants. Existing clinical trial guidance does not fully address issues specific to
BMS trials.
OBJECTIVES To establish newmethodological criteria to guide the design, conduct, analysis,
and reporting of BMS trials and to support clinical trialists designing and undertaking BMS
trials, editors and peer reviewers assessing trial reports for publication, and regulators
evaluating the safety, nutritional adequacy, and efficacy of BMS products.
DESIGN, SETTING, AND PARTICIPANTS Amodified Delphi methodwas conducted, involving
3 rounds of anonymous questionnaires and a face-to-face consensus meeting between
January 1 and October 24, 2018. Participants were 23 experts in BMS trials, BMS regulation,
trial methods, breastfeeding support, infant feeding research, andmedical publishing, and
were affiliated with institutions across Europe, North America, and Australasia. Guidance
development was supported by an industry consultation, analysis of methodological issues in
a sample of published BMS trials, and consultations with BMS trial participants and a research
ethics committee.
RESULTS An initial 73 criteria, derived from the literature, were sent to the experts. The final
consensus guidance contains 54 essential criteria and 4 recommended criteria. An 18-point
checklist summarizes the criteria that are specific to BMS trials. Key themes emphasized in
the guidance are research integrity and transparency of reporting, supporting breastfeeding
in trial participants, accurate description of trial interventions, and use of valid and
meaningful outcomemeasures.
CONCLUSIONS AND RELEVANCE Implementation of this guidance should enhance the quality
and validity of BMS trials, protect BMS trial participants, and better inform the infant nutrition
community about BMS products.
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B reastmilk substitutes (BMS) are important nutritionalproducts for infantswho are not receiving breastmilk.Most North American and European infants are ex-
posed to BMS during their first year.1 Infants are sensitive to
health effects of BMS owing to their early stage of develop-
mentwhenconsuming itandtheirpotentiallyhigh levelofBMS
exposurewhenBMSareusedas a sole sourceof nutrition. The
potential association of BMSwith population health is there-
foregreater than formanyothernutritionalproducts, andBMS
need a scientifically robust evidence base so that caregivers
and health care professionals can make informed feeding
choices.2,3 Clinical trials that test BMS safety and evaluate
changes in BMS composition or formulation are the founda-
tionof this evidencebase. Several groupshavequestioned the
methodological quality of published BMS trials and, in turn,
the robustness of their conclusions.4-9 Specific issues identi-
fied include risk of bias related to trial methods, lack of inde-
pendence from BMS manufacturers, and less stringent regu-
latory oversight comparedwithdrug trials.6,10-13 InBMS trials
in which some infants are breastfed at enrollment, trials may
also be failing to support the establishment andmaintenance
of breastfeeding in participants.6,14 These concerns, and the
specific issues related to designingBMS trials that answer rel-
evant scientific questions without undermining breastfeed-
ing, suggest a need for new guidance for BMS trials.
We undertook a Delphi consensus to develop new stan-
dards for BMS trials. The new standards aim to support trial-
ists in designing, conducting, analyzing, and reporting trials,
as well as support regulators, critical appraisers, and review-
ers in evaluatingBMS trial reports. The guidance relates to in-
tervention trials of BMS in infants enrolled prior to their first
birthday, designed to demonstrate adequate growth and tol-
eranceor other objectives. It is designed to complement other
guidance such as that published by the US Food and Drug
Administrationor theEuropeanFoodStandardsAgency,Good
Clinical Practice, orConsolidatedStandardsofReportingTrials
(CONSORT). Further details are summarized in the eAppen-
dix in the Supplement.
Methods
A 3-step Delphi consensus process was used to derive new
methodological guidance for BMS trials. This Delphi consen-
sus was undertaken between January 1 and September 30,
2018, with a consensus meeting on October 24, 2018. This
method enables aggregation of the anonymous and indepen-
dent opinionsof anexpert panel to reach consensusonagreed
criteria.15,16 It is a systematic process of sequential rounds
used to resolve clinical problems for which evidence is lim-
ited and theopinionof stakeholders is important butmight be
conflicting.17,18 We invited experts in BMS trials designed to
demonstrate adequate growth and tolerance, BMS trials with
otherobjectivessuchassupportinghealthandnutritionclaims,
BMS regulation, trial methods, breastfeeding support, infant
feeding research, andmedical publishing. Expertswere iden-
tified through literature review and consultation with others
working in these fields. Initial criteriaweredeveloped through
review of existing clinical trial and BMS guidance, regulatory
standards, and critical appraisals. We conducted 3 rounds of
email questionnaires to generate, score, and refine criteria
(Figure) and used published requirements for consensus19
(Table 1).20 The UKHealth Research Authority was consulted
andconfirmed that this studydidnot require approval by a re-
search ethics committee because it was not considered to be
researchonpatients. Informedconsentwasobtainedbyemail
from all study participants. The protocols for this Delphi pro-
cess and an associated systematic review are registered on
PROSPERO (CRD42018091928).21 See the eAppendix in the
Supplement for further details.
Each round of the Delphi surveywas piloted by the study
team prior to initiation, and experts were given 3 to 4 weeks
tocompleteeachround,withregularprompts tomaximizepar-
ticipation. The study team (K.J., B.H., andR.J.B.)wasnot part
of the Delphi process and did not vote on the criteria.
Delphi Round 1
Experts were asked to rate the importance of criteria that
formed the initial guidance, using theGRADE (GradingofRec-
ommendations, Assessment, Development and Evaluations)
scale: a score of 1 to 3 corresponds to “not important,” 4 to 6
to “important but not critical,” and 7 to 9 to “critical.”20 If ex-
perts thought they couldnot comment on a criterion, they se-
lected “unable to score.” Experts were also invited to provide
free text comments, suggest adjustments to thewordingof cri-
teria, or suggest newcriteria, and to comment on the scope of
the guidance. The study team (K.J. and R.J.B.) summarized
scores, anonymized comments, and classified criteria as es-
sential, recommended, consensusout, ornoconsensus, asde-
scribed inTable 1.20All criteria other than consensusoutwere
carried forward to round 2, together with proposed new cri-
teria, proposed edits to existing wording, and any proposed
mergingor splittingof criteria.All changesornewcriteriawere
highlighted in round 2, together with the anonymous com-
ments from round 1.
Delphi Round 2
Expertswere asked to rate the importance of the revised crite-
ria. For criteria repeated from round 1, expertswere shown the
consensusoutcomeand their ownscoring.Expertswereasked
Key Points
Question What is the best way to ensure the validity of clinical
trials of breast milk substitutes while protecting trial participants?
Findings Through a Delphi consensus project, guidance was
developed to address issues specific to trials of breast milk
substitutes assessing growth and tolerance, as well as trials of
breast milk substitutes with other objectives. This consensus
guidance summarizes best practice for the design, conduct,
analysis, and reporting of trials of breast milk substitutes.
Meaning Use of this guidance, in conjunction with existing clinical
trial regulations, should enhance the quality and validity of trials of
breast milk substitutes, protect trial participants, and support the
evidence base for infant nutrition recommendations.
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to reevaluate thecriteria in lightof theconsensusoutcomeand
propose further edits or comments, but could not addnewcri-
teria at this stage. Responseswere classified and criteriamodi-
fied in the same way as for round 1, but criteria that were still
classified as no consensus were removed after round 2.
Pilot Systematic Review
Apilot systematic reviewof a sample of recent BMS trialswas
undertakenby the study team (K.J., B.H., andR.J.B.) to evalu-
ate adherence to the preliminary criteria generated in round
2. The findings were summarized for experts before round 3.
Industry Consultation
Revised guidance after round2was sent to BMS industry rep-
resentatives for comment on the feasibility and relevance of
the proposed criteria. Breast milk substitute industry repre-
sentatives were not invited to score criteria, but their feed-
back was collated and added to the guidance document to
review in round 3.
Delphi Round 3
Experts were asked to review the revised criteria arising from
round2, togetherwiththefindingsof thesystematic reviewand
anonymized industry feedback. Experts were given an oppor-
tunity to suggest removal,merging, splitting, or changes to cri-
teria or their ratings. Through analysis of round 3 responses,
essential and recommended consensus criteriawere finalized.
Criteria for which the response to industry commentswas un-
resolved or conflicting comments were received during round
3werehighlightedfordiscussionduringtheconsensusmeeting.
ConsensusMeeting
Expertswere invited to attend the final consensusmeeting in
person or by web link. The meeting focused on criteria for
whichconsensushadnotyetbeenachieved.Each relevant cri-
terion was discussed until agreement was reached to retain,
edit, or remove it from the guidance. The meeting was facili-
tated by an independent nonvoting chair with experience in
BMS regulation, Peter Aggett, MD, PhD (University of Lan-
caster, UK). Experts were given the opportunity to comment
on each criterion, and for those who wished to raise issues
anonymously, opportunities were given to submit questions
or comments prior to or during the meeting, to be raised by
thechair on their behalf. The study team(K.J., B.H., andR.J.B.)
circulatedminutes after theconsensusmeeting, and themeet-
ingwas recorded.Any final edits and formatting changeswere
agreed on through email exchange after the meeting.
Trial Participant and Ethics Committee Consultation
After theconsensusmeeting, the final criteriawere sent topar-
ents of infants who had participated in a BMS trial and to the
London Riverside National Health Service Research Ethics
Committee for formal comment.
Figure. Summary of Delphi Consensus Process
73 Draft criteria circulated to panelStart:
51 Consensus in, 11 no consensus, 9 consensus out, 25 newEnd:
29 Consensus in, without or with only minor modification
22 Consensus in, with significant modification
11 No consensus
9 Consensus out (6) or merged with another criterion (3)
25 New criteria (21) or split into 2 criteria (2)
Pilot systematic review
Selective outcome reporting
identified as a potential issue 
Industry consultation 
General comments received, and specific
suggestions for 42 of the 69 criteria 
Round 1
87 Revised criteria circulated to panelStart:
69 Consensus in (64 essential, 5 recommended) 18 removedEnd:
60 Consensus in, without or with only minor modification
9 Consensus in, with significant modification
9 No consensus (removed)
9 Consensus out (1) or merged with other criteria (8)
0 Split into 2 criteria
Round 2
69 Revised criteria circulated to panel Start:
64 Essential, 5 recommended, none consensus outEnd:
• Number of criteria or level of recommendation did not change
• Modifications suggested to several criteria
• 19 Criteria highlighted for discussion at consensus meeting 
Consensus meeting  
• Discussed 19 criteria with unresolved issues relating to industry feedback
or round 3 comments, and reviewed scope of guidance and key definitions 
• 1 Criterion removed, 4 merged with existing criteria during meeting,
6 subsequent to meeting, 16 modified during meeting 
• Key issues discussed were: (1) transparency of trial conduct, reporting,
and adverse event coding; (2) study design and implications for
breastfeeding; (3) description of experimental and control BMS; and
(4) study end points
• All revised criteria reached consensus
Final guidance document
54 Essential and 4 recommended criteria
BMS trial checklist
18 Criteria specific to BMS trials
Round 3
A summary of the actions taken during each step of the Delphi consensus
process is shown. BMS indicates breast milk substitute.
Table 1. Definition of Consensus for the Delphi Process
Consensus
classificationa Description Definition
Essential Consensus that the criterion
is essential to the design or
conduct of BMS trials
≥70% Of experts
scoring as 7-9 and
<15% of experts
scoring as 1-3
Recommended Consensus that the criterion is
recommended with regard to
the design or conduct of BMS
trials
≥70% Of experts
scoring as 4-6 and
<15% of experts
scoring as 1-3
Out Consensus that the criterion
should not be included in the
core methodological criteria
≥70% Of experts
scoring as 1-3 and
<15% of experts
scoring as 7-9
No consensus Uncertainty about importance
of the criterion
Anything else
Abbreviations: BMS, breast milk substitute; GRADE, Grading of
Recommendations, Assessment, Development and Evaluations.
a Consensus classification used the GRADEmethod. A score of 1 to 3
corresponds to not important, a score of 4 to 6 to corresponds to important
but not critical, and a score of 7 to 9 corresponds to critical.20
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Results
Setting and Participants
ThisDelphi consensuswasundertakenbetween January 1 and
September 30, 2018,with a consensusmeetingonOctober 24,
2018. Twenty-eight experts were contacted and 23 partici-
pated in at least 1 stage of the Delphi survey: 6 clinical trial-
ists, 9 experts in BMS regulation, 5 clinical trial methodolo-
gists, 2 experts in breastfeeding support and infant feeding
research, and 1medical journal editor. Expertswere affiliated
with institutions in Europe, North America, and Australasia.
Sixteenof the expertswere able to contribute to the final con-
sensus meeting. Six of 7 invited BMS industry representa-
tives provided comments between June 1 and September 30,
2018, comprising representatives fromDanoneNutricia,Nestlé
Nutrition, Abbott Nutrition, Hipp, Friesland Campina, and
Dairy Goat Co-operative.
Delphi Survey Results
Initial guidance for round 1 included 73 criteria derived from
clinical trials, BMS and breastfeeding guidance, and apprais-
als of the BMS trial literature. General comments raised in
the BMS industry consultation related to overlap with exist-
ing clinical trial guidance, the value of study designs other
than randomized clinical trials, definitions of BMS and other
nutritional products, and the title and scope of the guidance.
Preliminary findings from the pilot phase of the systematic
review, which evaluated a sample of 61 recent BMS trials,
were a lack of independently funded studies and a high
prevalence of nonregistered trial outcomes highlighted in
publication abstracts.
Theoutcomes at each stageof theDelphi process are sum-
marized in theFigure. The final guidance comprises 54 essen-
tial criteria (eTable 1 in the Supplement) and 4 recommended
criteria (eTable 2 in the Supplement). Of these, 18 criteria are
specific to BMS trials, which are summarized as a checklist in
Table 2.20,22 The 58 criteria are elaborated in the eAppendix
in the Supplement, including a list of definitions for the key
termsused.Key issuesdiscussedat theconsensusmeetingcen-
tered around 4 themes.
Theme 1: Research Integrity and Reporting Transparency
Expertsstressedthe importanceof transparencyof trial conduct
and reporting: that all BMS trials are registered; that trial out-
comesaremadepubliclyavailable, in linewithcurrent initiatives
inmedical research that aim to increase access to original data
sets23-25;andthatoversightof trialconduct,analysis,andreport-
ing, including adverse event coding, is independent. Indepen-
dencewasconceptualizedasusuallymeaningthattrialoversight
was the responsibility of theprincipal investigator, and should
notbe the responsibilityof anemployeeof theBMS industryor
anyotherentitywithapotential financial interest intheoutcome
of the trial. Itwas thought that in-house industry-led statistical
planningandanalysis isnotappropriateunlessthere iscomplete
transparency owing to audit by regulators or full publication
ofparticipant-leveloutcomedata, suchthatall statistical analy-
sescanbe independentlyverified.WhenblindedBMSproducts
are used as trial interventions, industry collaboration may be
necessary,buttrialistsandBMSmanufacturersshouldavoidcre-
ating financialdependencies andavoid industry control of trial
conduct, analysis, or reporting. The TRIGR (Trial to Reduce
Insulin-DependentDiabetesMellitus in theGenetically atRisk)
study was cited as a good example of “arm’s length” BMS trial
practice, inwhichtheBMSmanufacturer’srolewaslimitedtopro-
vision of trial interventions.26 Experts also emphasized that
significant trial amendments—especiallychanges toparticipant
inclusioncriteria,experimentalorcontrol treatment,andmeth-
ods, timing,ornatureofoutcomemeasures—shouldberecorded
bywayof anupdate to theBMS trial’s recordonaWorldHealth
Organization–approved clinical trial registry.
Theme 2: Study Design and Breastfeeding Support
Theprovisionofbreastfeeding support inBMStrialswasacon-
troversial area, resolvedbyexperts through identifying the im-
portance of distinguishing 2 different approaches to breast-
feeding support for 2 different types of studies. In BMS trials
designed to meet a noninferiority or equivalence objective—
typically those aiming todemonstrate adequate infant growth
and toleranceof anewBMSproduct—experts thought thatpar-
ticipating infants shouldbe fullyBMS fedand thedecisionnot
touse breastmilk should be firmly establishedprior to enroll-
ment in the trial. After randomization, additional breastfeed-
ing support is not usually required for participants in these
studies, but it is important to ensure that appropriate breast-
feedingsupporthasbeenprovidedprior toenrollment. Insome
countries, regulatorshaveadditional specific requirements for
infant growth and tolerance trials—for example, in theUnited
States, growth trials must enroll infants at age 14 days or
youngerwith an intervention period that lasts for 15weeks or
more.27 Thesenoninferiority or equivalence trials shouldusu-
ally be analyzed using both intention-to-treat and a prespeci-
fied per-protocol data set.
In a separate group of BMS trials, usually pragmatic supe-
riority trials aiming to generate data to support a nutrition or
health claim, some infants are receiving breastmilk at enroll-
ment. Superiority trials should usually be analyzed using an
intention-to-treat data set. In trials inwhich some infants are
receiving breast milk at enrollment, experts agreed that it is
important to demonstrate adequate support for breast milk
feeding within the trial. In these studies, it was thought that
an international board–certified lactation consultant em-
ployedbyanacademicorhealth care institutionwouldbebest
placed to offer skilled breast milk feeding support.
Theme 3: Description of Trial Interventions
Experts confirmed the scope of this guidance as being BMS,
as defined by the World Health Organization, including all
ingredient additives to BMS that are delivered to an infant
within a BMS. Experts agreed that composition and formula-
tion of the experimental and control BMS need to be fully
described and related to existing marketed products, and
that the timing of the intervention period should be appro-
priate for the trial objectives. Trial participants’ intake of
both experimental and control BMS and any other foods
should be accurately recorded.
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Theme 4: Study Outcomes
Experts agreed that primary and secondary study outcomes
shouldbe clearly establishedapriori and that statistical power
calculations for theprimaryoutcomeshouldbebasedonaclini-
cally meaningful effect size. The end points used to measure
each outcome should be valid and clinically relevant, and the
useofsurrogateendpoints inplaceofclinicalendpointsshould
be appropriately justified and interpreted.
Table 2. Abbreviated Checklist of Criteria Specific for Clinical Trials of BMS
Domain, item No.a Consensus statement
BMS composition
and formulation
4a The trial protocol and trial reports clearly describe the composition and formulation of the
experimental and control BMS and their relationship, if any, to existing BMS products marketed
anywhere in the world
4b The experimental and control BMS both meet legally required compositional standards, and any
instructions for safe reconstitution of BMS by trial participants are consistent with relevant
national or international guidance
4c The trial protocol and trial reports clearly describe any differences between experimental and
control BMS which are additional to the constituent(s) of interest and consider their potential
impact on the trial results
4d Appropriate preclinical studies have been performed for previously untested components of BMS
Intervention
7a For trials with a primary noninferiority or equivalence objective, such as growth and tolerance
trials, participants should be exclusively BMS fed at enrollment
7b The trial protocol and trial reports describe how intake of experimental and control BMS is
recorded during the trial, and the trial reports summarize experimental and control BMS intake
in each treatment group during the intervention period
7c Trial participants’ intake of any foods other than experimental and control BMS during the
intervention and data collection periods is recorded
7d The age of infants at the start and end of the intervention period is appropriate for the trial
objectives, and the age range at enrollment is sufficiently narrow for treatment effects to be
comparable across the trial population
Outcome
assessment
8c For growth outcomes, trial reports should comment on whether metabolic and developmental
outcomes were also evaluated
Analysis
12b Statistical analyses which were not prespecified in the trial protocol are interpreted with caution
and are not used as the basis for claims in the trial conclusions, or to support recommendations
for infant feeding
Ethics for trials in
BMS-fed infants
14 For trials where participants are all exclusively BMS fed at enrollment, such as growth and
tolerance trials, carers’ decision not to breastfeed should be firmly established prior to
enrollment in the trial
Ethics for trials
where some
participants
consume breast
milkb
15a The ethics statement in the trial protocol and trial reports clearly states how breastfeeding was
supported during the trial
15b Trial methods do not involve anything that may be interpreted as an incentive to introduce
BMS to an infant’s diet and emphasize the superiority of breastfeeding over BMS in all literature
15c Randomization and treatment allocation do not occur until the time point when a participant
expresses an intention to introduce BMS, and participants are offered skilled breastfeeding
support from a trained breastfeeding counselor at this stage, prior to randomization and
introduction of experimental and control BMS
15d Incentives to participate in the trial do not include provision of free or discounted BMS, samples,
equipment, or other gifts related to BMS and its marketing; if free or discounted BMS is felt to be
essential, then a similar level of reimbursement should be provided for continued breast milk
feedingc
15e For trials which involve groups of infants at increased risk of a severe adverse event related to
BMS use, a high level of scrutiny regarding the possibility of a negative impact on breast milk
feeding is requiredc
Limitations
19c Trial reports discuss the limitations of any findings which are based on analysis of participants
with a minimum level of experimental or control BMS intakec
Conflict of interests
20d An investigator who is independent of the BMS industry takes overall responsibility for the
conduct of the trial, planning and conduct of statistical analyses, decision to publish, reporting,
and interpretation of the trial findings, and ensures that the planning and conduct of statistical
analyses are led independently of the BMS industry
Abbreviations: BMS, breast milk
substitute; GRADE, Grading of
Recommendations, Assessment,
Development and Evaluations.
a Item No. refers to the full criteria in
eTables 1 and 2 in the Supplement.
Criteria were scored using the
GRADE scale.20
b For growth and tolerance trials, or
other trials with noninferiority or
equivalence objectives, participants
should be fully BMS fed and the
decision not to breastfeed should
be firmly established prior to
enrollment in the trial. For other
trials, where some participants may
be receiving breast milk at
enrollment or during the
intervention period, trial design and
conduct should comply with the
International Code of Marketing of
Breast-milk Substitutes22 and
subsequent relevantWorld Health
Assembly resolutions to avoid
undermining breast milk feeding.
c Recommended criteria. All other
criteria were classified as essential
(Table 1).
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Trial Participant Viewpoints
After the consensus meeting, 16 BMS trial participants were
contacted and 5 responded, with 3 providing detailed com-
mentary and telephone discussion regarding the criteria. All
responding BMS trial participants were supportive of the fi-
nal criteria, especially independenceof trial conductandanaly-
sis and transparent reporting of outcomes. The BMS trial par-
ticipants commented in detail on 2 criteria concerning the
subset ofBMS trials inwhich some infants are receivingbreast
milk at enrollment. These criteria (15c and 15d) are not rel-
evant to trials in which infants are exclusively fed BMS prior
to enrollment and the parents’ decision to not provide breast
milk is firmlyestablishedprior toenrollment. In supportof cri-
terion 15c, they thought that provisionof trial BMS shouldnot
occur until randomization, and that this provision should not
occur during pregnancy or (where relevant) during exclusive
breastmilk feeding, toavoidprovidingan incentive touseBMS
inplaceofbreastmilk.However,participants thought thatonce
aparentdecides tosupplementbreastmilk feedingwithaBMS,
theuseofotherBMSproducts shouldbepermittedprior topro-
vision of trial BMS, to avoid feeding problemswhile awaiting
delivery of the experimental or control BMS. In relation to cri-
terion 15d, BMS trial participants viewed the provision of free
trial BMS as useful, and supportive for participants with fi-
nancial constraints, but recognized that this provisionmay in-
centivize breastfeeding women to use BMS in place of breast
milk. One participant suggested that if free BMS is provided
in a trial that includes breastfed infants, a financial incentive
to continue breastfeeding could also be provided. The ex-
perts agreed by email to add this suggestion to criterion 15d.
Discussion
Clinical trials of BMS require specific guidance to ensure that
they aremethodologically sound, such that their resultsmay
reliably inform caregivers and health care professionals. This
Delphi survey has derived, through expert consensus, a stan-
dard consisting of 58 criteria to support the design, conduct,
analysis, transparent reporting, and evaluation of BMS trials.
Implementation of this standard, in conjunction with exist-
ing methodological and ethical guidance, could better pro-
tect BMS trial participants and ultimately improve the qual-
ity of BMSproducts and information associatedwith them for
consumers.
The validity of this Delphi process is supported by the ex-
tensive reviewof relevant sources that informed the initial cri-
teria and the engagement of a comprehensive panel of ex-
pertswhoprovided adiverse range of experience and insight.
The consistent and anonymous application of each iteration,
as defined a priori in the protocol, minimized bias and ma-
nipulation of experts’ opinions. Outcomes from analysis of a
sample of BMS trials identified by a pilot systematic review
usefully informed theDelphi process. The inclusion of a face-
to-face consensus meeting resolved any remaining issues. It
wasnotpossible tomaintainanonymityofexpertsat this stage,
but the meeting was carefully moderated by an independent
chair, through whom experts were invited to submit ques-
tionsor issues anonymously.Althoughonly 13of 23Delphi ex-
perts attended the meeting, 3 others provided written com-
ments thatwereconsideredduringthemeeting;a full summary
of the discussions and decisions, and then the final manu-
script, were shared with all experts for comment and ap-
proval after the meeting. One expert withdrew from author-
shipof thearticlebecauseofdisagreementwithspecificcriteria,
although thesemet the predefined requirements for consen-
sus summarized in Table 1.20 To limit bias introduced during
developmentof the criteria, the study teamreproducedall ex-
perts’ comments anonymously and verbatim in each round.
Industry representatives were asked to comment, but not to
score the criteria.
Limitations
This study had some limitations. We had good representa-
tion from Europe and North America, where most BMS trials
are conducted, but less good representation from other re-
gionswhere BMS trials are less commonly conducted.Wedid
not involve industry in thewholeDelphi process, because that
would represent a conflict of interest for some experts in re-
lation to their regulatory work. This new guidance therefore
represents theviewsof trialists,methodologists, lactationcon-
sultants, infant feeding researchers, regulators, and a journal
editor rather than the views of industry representatives. Par-
ents of infants who had participated in a BMS trial com-
mented on the criteria at the final stage but were not mem-
bers of the Delphi panel and did not score criteria.
Conclusions
Wehavedevelopednew,consensus-basedguidance for thede-
sign, conduct, analysis, and reportingofBMS trials. Toachieve
our aimof improving the conduct and reporting of BMS trials,
this guidance must come to represent the expected standard
in this field. Industry representatives, regulators, and clinical
trialists have been able to contribute their views on the feasi-
bilityandpracticalityof thesecriteria,andsomeregulatorssuch
as Health Canada have already incorporated the criteria into
their guidance.28 If BMS trialists incorporate this guidance in
their clinical trials, in conjunctionwith existingmethodologi-
cal andethical guidance, thequality andvalidity of their trials
will benefit, so participants will be protected and the infant
nutrition communitywill be better informed about the safety
and potential efficacy of BMS products.
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